High-Dose Infliximab Therapy in Crohn’s Disease: Clinical Experience, Safety, and Efficacy

BACKGROUND: Inadequate response to infliximab [IFX] therapy in Crohn’s disease [CD] may necessitate dose intensification. We evaluated safety and efficacy of high-dose IFX [HD IFX] [greater than 10mg/kg every 8 weeks] in CD and characterized predictors of response to HD IFX intensification. METHODS:...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Crohns Colitis
Asıl Yazarlar: Hendler, Steven A, Cohen, Benjamin L, Colombel, Jean-Frédéric, Sands, Bruce E, Mayer, Lloyd, Agarwal, Shradha
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2015
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497242/
https://ncbi.nlm.nih.gov/pubmed/25540149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jju026
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller